Indian Journal of Medical Biochemistry

Register      Login

VOLUME 28 , ISSUE 1 ( January-April, 2024 ) > List of Articles


Glycemic Variability in Different Stages of Chronic Kidney Disease with Type 2 Diabetes Mellitus: A Cross-sectional Study

Sapna Gupta, Nivedita Priya

Keywords : Chronic kidney disease, Diabetic nephropathy, Estimated glomerular filtration rate, HbA1c, Renal anemia, Type 2 diabetes mellitus

Citation Information : Gupta S, Priya N. Glycemic Variability in Different Stages of Chronic Kidney Disease with Type 2 Diabetes Mellitus: A Cross-sectional Study. Indian J Med Biochem 2024; 28 (1):1-7.

DOI: 10.5005/jp-journals-10054-0228

License: CC BY-NC 4.0

Published Online: 20-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Aim and background: Hemoglobin A1c levels and complete blood count (CBC) is a diagnostic test used for diabetes and to determine the development of diabetic complications. The level of HbA1c is affected by factors, such as the Hb, the age of red blood cells (RBCs) in the blood circulation, and the Hb glycation rate. Our study aims to assess glycemic variability (GV) in diabetic patients at different stages of chronic kidney disease (CKD) and its relation to Hb and RBC levels to their HbA1c in different CKD stages. Materials and methods: This was a cross-sectional analysis of 156 adults with type 2 diabetes mellitus (T2DM) carried out in Parul Sevashram Hospital, Vadodara from November 2022 to May 2023. Chronic kidney disease stages were defined according to the modification of diet in renal disease (MDRD) equation stages I-V. HbA1c, RBC count, and RBS were estimated for the patients belonging to each stage. Statistical analyses were performed using SPSS software version 26.0 and Microsoft Excel 2019. Results: Out of the total diagnosed patients (n = 156), 58.3% were males and 41.6% were females. It was important to note that the maximum number of patients in the end-stage, that is, stage V, was detected with the HbA1c range of 4–7%. The inconsistencies in blood sugar levels with HbA1c were an alarming indication of other underlying issues such as renal anemia. Conclusion: Chronic kidney disease occurs due to diabetes and hypertension also contributes to renal anemia. In the later stages of CKD with T2DM, a low level of HbA1c ranging from 4 to 7% has been found due to low RBC count and Hb. Therefore, the clinical significance of this study is the non-reliability of HbA1c tests in advanced stages of CKD patients because of lower RBC counts giving rise to false glycated hemoglobin percentage.

PDF Share
  1. Subramanyam KS, Gosavi S, Tenneti D, et al. Evaluation of the role of hba1c in chronic kidney disease. J Clin Diagn Res 2018;12(7): BC01–BC04. DOI: 10.7860/JCDR/2018/34732.11732.
  2. National Kidney Foundation. How to classify CKD [internet]. 2015. Available from:
  3. Britannica, The Editors of Encyclopedia. “Diabetes Mellitus”. Encyclopedia Britannica, 24 Oct. 2023.
  4. Ren J, Dai C. Pathophysiology of chronic kidney disease. In: Yang, J, He W. (eds). Chronic Kidney Disease. Singapore: Springer; 2020. DOI: 10.1007/978-981-32-9131-7_2.
  5. Wheeler DC, James J, Patel D, et al. SGLT2 inhibitors: Slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Ther 2020;11(12):2757–2774. DOI: 10.1007/s13300-020-00930-x.
  6. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: Prevalence, temporal trends, and treatment patterns—NHANES 2007–2012. BMJ Open Diabetes Res Care 2016;4:e000154. DOI: 10.1136/BMJDRC-2015-000154.
  7. Sherwani SI, Khan HA, Ekhzaimy A, et al. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights 2016;11:95–104. DOI: 10.4137/BMI.S38440.
  8. Matovinović MS. 1. Pathophysiology and classification of kidney diseases. EJIFCC 2009;20(1):2–11. PMID: 27683321.
  9. Neumiller JJ, Hirsch IB. Management of hyperglycemia in diabetic kidney disease. Diabetes Spectr 2015;28(3):214–219. DOI: 10.2337/diaspect.28.3.214.
  10. Duggal D et al. HbA1c (Hemoglobin A1c) A1c chart, Test Levels, & Normal Range. April 20, 2022. Available from:
  11. Dean AG, Sullivan KM, Soe MM. Open Epi: Open Source Epidemiologic Statistics for Public Health, Version., updated 2013/04/06, accessed 2023/11/03.
  12. No author listed. Nutritional anemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968;405:5–37. PMID: 4975372.
  13. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49(Suppl 2): S12–154. DOI: 10.1053/j.ajkd.2006.12.005.
  14. Joshi R, Subedi P, Yadav GK, et al. Prevalence and risk factors of chronic kidney disease among patients with type 2 diabetes mellitus at a tertiary care hospital in Nepal: A cross-sectional study. BMJ Open 2023;13:e067238. DOI: 10.1136/bmjopen-2022-067238.
  15. Alrawahi AH, Rizvi SGA, Al-Riyami D, et al. Prevalence and risk factors of diabetic nephropathy in Omani type 2 diabetics in Al-Dakhiliyah region. Oman Med J 2012;27:212–216. DOI: 10.5001/omj.2012.48.
  16. Bailey RA, Wang Y, Zhu V, et al. Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on kidney disease: Improving global outcomes (KDIGO) staging. BMC Res Notes 2014;7:415. DOI: 10.1186/1756-0500-7-415.
  17. Yusof Khan AHK, Zakaria NF, Zainal Abidin MA, et al. Prevalence of glycemic variability and factors associated with the glycemic arrays among end-stage kidney disease patients on chronic haemodialysis: Medicine 2021;100:30. DOI: 10.1097/MD.0000000000026729.
  18. Jin YP, Su XF, Yin GP, et al. Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy. J Diabetes Complications 2015;29:395–399. DOI: 10.1016/j.jdiacomp.2014.12.015.
  19. Sato Y, Yanagita M. Renal anemia: From incurable to curable. Am J Physiol Renal Physiol 2013;305(9):F1239–1248. DOI: 10.1152/ajprenal.00233.2013.
  20. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006 69:560–564. DOI: 10.1038/
  21. Monnier L, Colette C, Owens D. The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts. Diabetes Res Clin Pract 2012;95:303–311. DOI: 10.1016/j.diabres.2011.10.014.
  22. Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005;21:989–998. DOI: 10.1185/030079905x49662.
  23. Hutchinson FN, Jones WJ. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Am J Kidney Dis 1997 May;29(5):651–657. DOI: 10.1016/s0272-6386(97)90116-5.
  24. Agarwal R, Light RP. Relationship between glycosylated hemoglobin and blood glucose during progression of chronic kidney disease. Am J Nephrol 2011;34:32–41. DOI: 10.1159/000328737.
  25. Christy AL, Manjrekar PA, Babu RP, et al. Influence of iron deficiency anemia on hemoglobin A1c levels in diabetic individuals with controlled plasma glucose levels. Iran Biomed J 2014;18(2):88–93. DOI: 10.6091/ibj.1257.2014.
  26. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne) 2021;8:642296. DOI: 10.3389/fmed.2021.642296.
  27. Astor BC, Coresh J, Heiss G, et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: The atherosclerosis risk in communities (ARIC) study. Am Hear J 2006;151:492–500. DOI: 10.1016/j.ahj.2005.03.055.
  28. Freedman BI, Shihabi ZK, Andries L, et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 2010;31(5):375–379. DOI: 10.1159/000287561.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.